Cancer Immunotherapy

Early Results of INF-(alpha) for Renal Carcinoma are Mixed

Published in Cancer Weekly, February 22nd, 1999

Benefits of subcutaneous administration of interferon alpha (INF-(alpha)) for metastatic renal carcinoma need to be balanced with the risks.

A. Ritchie and colleagues from the Cancer Trials Office, England, reported early clinical trial results of IFN-(alpha) for the treatment of metastatic renal carcinoma ("Interferon-Alpha and Survival in Metastatic Renal Carcinoma: Early Results of a Randomized Controlled Trial," Lancet, January 2, 1999;353(9146):14-17).

"Metastatic renal carcinoma has a 2-year survival of around 20 percent and is largely resistant to chemotherapy," wrote Ritchie et al. "The use of interferons in the treatment of metastatic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry